Coronary disease & ACSSecondary analysis
Rates of Sudden Death After Myocardial Infarction—Insights From the VALIANT and PARADISE-MI Trials
- Secondary analysis of the VALIANT and PARADISE-MI randomised trials
- multicentre
Authors' conclusion
After AMI, the risk of sudden death/RCA was highest in the first month, declining rapidly thereafter. Results revealed that compared with counterparts from 20 years ago, the rate of sudden death/RCA in patients with a reduced left ventricular ejection fraction and/or pulmonary congestion was 2- to 3-fold lower in people receiving contemporary management.
Study context
- Population
- Patients after acute MI complicated by pulmonary congestion and/or LV dysfunction
- Participants
- 5,661 / 9,617 / 14,703
- Comparison
- PARADISE-MI vs VALIANT cohort
- PARADISE-MIn = 5,661
- VALIANT (PARADISE-MI-like)n = 9,617reference
- VALIANT (total)n = 14,703
Primary result
As reported in the abstract
Sudden death/RCA
Further findings
| Outcome | PARADISE-MI | VALIANT (PARADISE-MI-like) | VALIANT (total) |
|---|---|---|---|
| Sudden death rate in first month after infarction | 9.5 (95% CI 7.0–12.7) per 100 person-years | Not reported in the abstract | Not reported in the abstract |
- Sudden death rate in first month after infarction: VALIANT 19.3 (95% CI 16.4–22.6) per 100 person-years
Sudden death rate in first month after infarction
- Rates highest in first month in both trials, declining steadily thereafter
Treatment
- PARADISE-MI more often treated with PCI for qualifying acute myocardial infarction (AMI) and more frequently received β-blocker, statin and MRA
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Rates of Sudden Death After Myocardial Infarction—Insights From the VALIANT and PARADISE-MI Trials. JAMA Cardiol. Published 1 October 2024. doi:10.1001/jamacardio.2024.2356
Summarised from the published abstract; every number is checked against it